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Abstract
It has become apparent that Mycobacterium mucogenicum isolates recovered from clinical samples are more diverse than was previously
realized and include an increasing number of emerging pathogens, as depicted by multilocus sequence analysis. Most clinically signiﬁcant
cases of those organisms involved catheter-related infections. They are susceptible to most antimicrobial agents, but like other rapidly
growing mycobacteria, they are resistant to ﬁrst-line antituberculous agents. A review of the cases of M. mucogenicum complex infection
in the literature is addressed here, as well as two additional cases of the closely related species Mycobacterium aubagnense.
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Introduction
Based on multilocus sequence analysis, the Mycobacterium mu-
cogenicum group comprises M. mucogenicum, Mycobacterium
aubagnense and Mycobacterium phocaicum [1,2]. This group of
organisms was ﬁrst named Mycobacterium chelonae-like
organism in 1982 and was reported as the etiologic agent in a
peritonitis outbreak involving two peritoneal dialysis units [3].
Springer et al. [4] proposed the name M. mucogenicum for this
group of organisms, reﬂecting the highly mucoid character of
the isolates. While the 16S rRNA gene sequence of the
M. aubagnense type strain differed from that of the M. muco-
genicum type strain by 14 base pairs, M. phocaicum shared
100% similarity [2]. The ecological niche of the M. mucogen-
cum group is unknown but this species seems ubiquitous and
contaminated water is a likely source of nosocomial infections
[5–7]. Members of this group are present in both public and
hospital water systems, where their persistence in bioﬁlms
and amoeba is enabled by their ability to tolerate disinfec-
tants, chlorination and extreme temperatures [6–11]. How-
ever, the epidemiology of infection due to rapidly growing
mycobacteria (RGM) in nine public hospitals in Spain recently
showed that M. mucogenicum isolates were clinically not
signiﬁcant [12]. Recently, chili sauces sold by street venders
in Mexico have been identiﬁed as a potential source of
M. mucogenicum infection [13].
Several studies have isolated M. mucogenicum-like strains
from clinical samples [14,15] which suggested that the
M. mucogenicum group is more diverse than was previously
realized. M. aubagnense and M. phocaicum were recently dis-
criminated among the M. mucogenicum group; it is possible
that the clinical spectrum of infection due to M. aubagnense
and M. phocaicum overlapped with that of infection due to
M. mucogenicum as described in previous reports.
I therefore describe two additional cases of M. aubagn-
ense infection and review the previously published cases of
M. mucogenicum.
Infection with M. mucogenicum
Mycobacterium mucogenicum isolates are associated with a
wide spectrum of clinical disease in both immunocompetent
and immunosuppressed individuals. They are also commonly
implicated in outbreaks of infection resulting from contami-
nated hospital equipment and water sources.
Catheter-related infections
Mycobacterium mucogenicum was originally discovered in two
outbreaks of peritonitis in 1976 and 1978 in 5/22 (18%) and
5/8 (63%) patients, respectively, undergoing intermittent
chronic peritoneal dialysis [3]. Seven sporadic cases of M. mu-
cogenicum peritonitis were further diagnosed in the same two
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centres. Investigations suggested that ineffective disinfection
of the equipment followed by colonization of the machines
with M. mucogenicum was responsible for the outbreaks [3].
In 1985, Bolan et al. [16] described a mycobacterial out-
break in a hemodialysis centre in Louisiana, USA. Among 26
isolates, 25 were identiﬁed as M. abscessus and one as
M. mucogenicum. The single factor common to all patients
was exposure to hemodialyzers (artiﬁcial kidneys) that had
been treated with a formaldehyde concentration that was
below effective levels for these RGM species [16].
Catheter-related infections are the most clinically signiﬁ-
cant cases of M. mucogenicum infection [17]. These infections
can be local or systemic. In one study, M. mucogenicum was
responsible for 23/44 (52%) bloodstream and catheter-
related infections in patients who had a primary diagnosis of
cancer and a consecutive diagnosis of M. abscessus 6/44
(14%) and M. fortuitum 6/44 (14%) infection [14].
In contrast, in a study by Gaviria et al., [18], M. mucogeni-
cum was responsible for 2/23 (9%) of catheter-related infec-
tions in haematopoietic stem cell transplant recipients while
M. abscessus accounted for 10/23 (43%), M. fortuitum for 6/23
(26%) and Mycobacterium chelonae for 5/23 (22%). Contamina-
tion of the catheter during bathing, where catheters were
exposed to shower (poured) water, was found to be the
route of infection due to M. mucogenicum in an outbreak of
bactaeremia among ﬁve bone marrow transplant patients and
one oncology patient at a tertiary-care hospital in Minnesota
[6] and in ﬁve paediatric haematology-oncology patients in
Israel, four of whom had fever and one had signs of an exit-
site infection [7]. Suboptimal water chlorination may also con-
tribute to the latter outbreak [7]. A cord blood transplant
recipient who developed a central venous catheter (CVC)
infection after the patient herself had ﬂushed her catheter
with tap water was also reported [19]. Hawkins et al. [20]
conducted a retrospective single-centre review of RGM cath-
eter-related blood stream infections. RGMs isolated from
blood cultures of six patients included M. mucogenicum
(n = 2), M. fortuitum (n = 2), Mycobacterium neoaurum (n = 1)
and Mycobacterium septicum (n = 1). In a later study, an
M. mucogenicum cluster represented an increasing trend in
catheter-related blood stream infections rather than an out-
break, given the distinct susceptibility patterns and the lack of
obvious epidemiological links [20]. Review of the literature
revealed ten well documented cases of catheter-related infec-
tion (Table 1). Most commonly, long-term central indwelling
catheters, e.g. a Hickman catheter, port-a-cath and peripheral
inserted central catheters, are incriminated. Anticancer che-
motherapy often requires the use of indwelling CVCs. Fever
was the most common clinical symptom in cases of M. muco-
genicum bactaeremia, except in the case of a patient receiving
acyclovir, ﬂuconazole and amoxicillin for post-transplantation
prophylaxis. The fact that M. mucogenicum isolates are suscep-
tible to antibiotics, including amoxicillin and amoxicillin-clavul-
anic acid [2], may explain why this patient remained apyretic.
Most reports have described infections in neutropenic and
non-neutropenic cancer patients. Only one patient died, pre-
sumably from the disseminated rhadomyosarcoma (Table 1).
Central nervous system diseases
Central nervous system (CNS) diseases involving M. mucogeni-
cum are rare but serious. Both immunosuppressed and immu-
nocompetent patients may develop CNS diseases. Among 87
reported cases of M. mucogenicum isolates, only two cases
without clinical data have been mentioned; both occurred in
AIDS patients. For one of the two patients, multiple cerebro-
spinal ﬂuid samples were AFB smear positive for an unrelated
reason 3 weeks prior to lumbar puncture [17]. This organism
has also been reported to have caused two fatal cases of menin-
gitis in immunocompetent patients. It is unlikely that M. muco-
genicum meningitis was nosocomial. In one case, this organism
was the aetiological agent of cerebral thrombophlebitis [21].
Respiratory infection
In 1993, Wallace et al. [17] evaluated 87 sporadic isolates of
M. mucogenicum. Among these isolates, 54 (62%) were iso-
lated from the respiratory tract and only two (4%), both
from AIDS patients, were clinically signiﬁcant. Infections
caused by the remaining 33 non-respiratory tract isolates
included post-traumatic wound infections and catheter-
related sepsis. Recovery of M. mucogenicum from skin,
wound or blood cultures was most often associated with
clinical disease. In contrast, a single positive sputum culture
was almost never clinically signiﬁcant.
The frequent presence of this organism in tap water,
including ice machines [22], may contribute to the transient
colonization or contamination of sputum samples [17].
Han et al. [14] reported that, among 28 cases of deﬁnite
and probable respiratory tract infections, M. mucogenicum
accounted for 11% (three cases) whereas M. abscessus
accounted for 64% (18 cases) and M. fortuitum for 14% (four
cases). The rare isolation of M. mucogenicum from respira-
tory specimens could also be due, in part, to pre-treatment
with mucolytics and sodium hydroxide and the addition of
antibiotics to the culture medium which might inactivate this
organism more than other RGMs because of its mucoid cell
surface and low resistance to antibiotics [14].
Skin and soft tissue infection
RGM cause post-traumatic skin infections. Recently, a skin
infection due to M. mucogenicum in a patient treated with
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the TNF-a antagonist etanercept, who had not had a preced-
ing soft tissue injury, was reported [23]. A 61-year-old
woman presented with a 3-month history of recurring
asymptomatic bumps on her legs. These lesions would peri-
odically ulcerate and drain a cloudy, yellow exudate. The
patient suffered from rheumatoid arthritis, managed with
low-dose prednisone and etanercept. The patient reported
feeling well. She excluded any exposure to whirlpool foot-
baths, though she did frequently have pedicures in a nail
salon. The patient did not recall any previous leg injury.
Examination revealed several ﬁrm, erythematous papules on
her legs, as well as several deeper dermal to subcutaneous
nodules near her ankles. Several of the lesions had overlying
erosion. No inguinal adenopathy was noted. An incisional
biopsy was performed from a deep nodule near her ankle.
Histological examination of this lesion showed necrotizing,
granulomatous inﬂammation with mycobacteria identiﬁed on
an acid fast stain. Additionally, a culture grew M. mucogeni-
cum. Her therapy entailed both discontinuation of the eta-
nercept and initiation of systemic antimicrobials. Based on
the identiﬁed susceptibilities of the isolates of M. mucogeni-
cum, treatment with clarithromycin 500 mg BID and minocy-
cline 100 mg BID was initiated. Continuous treatment with
these medications is planned for 6 months and further
follow-up is pending.
Another case of skin infection involved an 11-year-old
female who presented with erythematous nodules which felt
warm and were painful (some of them were conﬂuent), with
central ulceration and purulent exudation, located in the side
and posterior faces of both lower members (Figs 1 and 2). She
did not present with fever or any other systemic clinical sign.
As for antecedents, she referred to a wound in the popliteal
cavity after an accidental fall into a pool which evolved later
into an abscess; the remainder of the lesions appeared after
depilation with cold wax.
The conventional bacteriological and mycological cultures
of the exudates were negative. Then, it was decided to per-
form two punch biopsies and one of the nodules was used
for microbiological and anatomo-pathological studies. In the
derma, the histological inspection showed inﬂammatory inﬁl-
trates with polymorphonuclear leucocytes and a tendency of
suppurative granuloma formation (Figs 3 and 4).
The Ziehl–Neelsen, Fite-Faraco, periodic acid Schiff (PAS)
and PAS-diastase stainings were negative. The culture on
Lo¨wenstein medium at 30C showed creamy, non-pigmented
colonies of AFB, identiﬁed as M. mucogenicum. The patient was
treated with clarithromycin, in doses of 500 mg each 12 h for
5 months. The lesions evolved favourably but small plaque of
atrophic aspect and off-white peri-lesional halo remained [24].
Infection with M. aubagnense
We initially described M. aubagnense without clinical data [2].
Here, I report two cases related to these isolates in two
patients from a hospital in Marseille, France. The ﬁrst patient
FIG. 1. Erythematous nodules in the side and posterior faces of the
left lower member [24].
FIG. 3. Histological ﬁndings in the derma: inﬂammatory inﬁltrates
with polymorphonuclear leucocytes [24].
FIG. 2. Erythematous nodules in the side and posterior faces of the
right lower member [24].
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was a 55-year-old man with a history of tobacco abuse (one
pack/day) who was admitted with hemoptysis and bilateral
ﬁbrosis lesion suggestive of pulmonary tuberculosis. Comput-
erized tomography revealed thickening of left pleura and non-
systematized opacity of the right lung. Microscopic observa-
tion of the bloody mucoid bronchial aspirate lavage after
Ziehl–Neelsen staining disclosed epithelial cells and numerous
polymorphonuclear leucocytes but no AFB. Cultures of the
bronchial aspirate lavage and two further sputum specimens
revealed the presence of the same isolate, identiﬁed as an
organism closely related toM. mucogenicum. This organism was
later identiﬁed as M. aubagnense. On the basis of susceptibility
data obtained for this isolate, a regime including clarithromycin
plus amikacin was prescribed and proved to be well tolerated
by the patient. The bacteriological results (two additional spu-
tum specimens were negative for AFB by smear and culture)
were conclusive and the clinical response was favourable.
The second patient was a 91-year-old woman who under-
went hip prosthesis revision because of suspected sepsis
(with fever at 39C). An X-ray revealed bone lyses with
necrosis and pathological fracture. Microbiological investiga-
tions of the joint ﬂuid collected at the time of surgery
revealed the presence of an organism closely related to
M. mucogenicum, whereas Gram staining revealed no bacteria.
Colonies were formed in pure culture after 4-day inoculation
onto Middelbrook 7H10 and 5% sheep-blood agar at 37C in
a 5% CO2 atmosphere. The organism was later identiﬁed as
M. aubagnense. Amikacin and imipenem therapy was success-
ful and the patient’s condition improved without much pain
and she was referred for rehabilitation.
Infection with M. phocaicum
M. phocaicum which is undistinguishable from M. mucogenicum
using 16S rRNA [2] was identiﬁed in two hospitalized oncol-
ogy patients with bloodstream infection in a Texas hospital
using rpoB gene sequencing. A multiphasic approach showed
later that one of the isolates matched an environmental iso-
late from a swab of a hand shower in the patient’s room [5].
This outbreak was the ﬁrst of a catheter-associated bactera-
emia caused by M. phocaicum and the ﬁrst report of a clinical
isolate from a US hospital, although their identiﬁcation may
overlap with that of M. mucogenicum in previous reports.
This organism has also been isolated from respiratory secre-
tions [2] and from the therapy pool water in a hospital in
Marseille [25]. An investigation which was undertaken to
determine the Mycobacterium species responsible for the his-
tological changes consistent with mycobacteriosis observed
during routine screening of zebraﬁsh at a research facility
revealed the presence of M. phocaicum in the tank or tubing
surface bioﬁlms but not in the zebraﬁsh [26]. Furthermore,
M. phocaicum represented 18% of amoeba-associated myco-
bacterial species in three cooling towers located in the
centre of Paris, France [27].
Miscellaneous Diseases
The case of a rapidly progressive granulomatous hepatitis
caused by M. mucogenicum was reported in a 51 year-old man,
a retired anthracite coal miner. Signiﬁcant in his social proﬁle
was a history of tobacco abuse (90 packs/year) and remote
alcohol use. Signiﬁcant in his medical history were hypothy-
roidism, arthritis and a questionable diagnosis of coal worker’s
pneumoconiosis. The patient died because of multi-organ fail-
ure secondary to gram-negative sepsis. Autopsy liver cultures
revealed the presence of M. mucogenicum colonies [28].
M. mucogenicum was recently identiﬁed in a surgically-
resected, formalin-ﬁxed, parafﬁn-embedded specimen from
one of 11 patients with Crohn’s disease. Mycobacterium tuber-
culosis was identiﬁed in two cases; Mycobacterium avium
subsp. paratuberculosis was not identiﬁed in any. The patient
infected with M. mucogenicum was a 22-year old man who
presented with abdominal pain, vomiting and tarry stool. He
had undergone ileal resection for a perforation at the distal
ileum; the postoperative complications included functional
bowel disturbance and constipation [29].
The scope of disease caused by M. mucogenicum could
include disseminated infection. This organism was found to
be responsible for bacteraemia in a patient with cirrhosis.
No localizing signs of infection were present, although the
patient had a CVC in situ for haemodialysis. The patient died
as a result of hepatic and renal failure [30].
A case of M. mucogenicum sepsis in an immunocompetent
woman with Munchausen syndrome with multiple abscesses
FIG. 4. Histological ﬁndings in the derma: tendency of suppurative
granuloma formation.
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has been reported. M. mucogenicuum was isolated from the
blood 12 days after insertion of a CVC and 42 days after the
cervical node biopsy [31].
Vargas et al. [32] reported M. mucogenicum to be the cause
of disseminated infection in a patient with idiopathic CD4+ T
lymphocytopenia with prolonged fever of unknown origin.
The patient had no relevant history of disease or exposure.
Identiﬁcation of M. mucogenicum Complex
Species
Occasionally, interpretation of the Gram stain of a positive
blood culture can be difﬁcult; if there is a low bacterial load,
no organisms can be seen [33]. M. mucogenicum isolates
appear as Gram-positive bacteria on Gram stain and on
sheep blood and chocolate agar.
Based on the positive catalase reaction, the isolate can be
easily misidentiﬁed as Corynebacterium or Nocardia species
[33,34]. Also, Gram stain of wound drainage often reveals
leucocytes with no visible organisms. Acid-fast stains are
often positive. M. mucogenicum complex organisms can be
cultivated in Lowenstein-agar or even routine culture media.
Evidence of growth usually occurs within 3–7 days of inocu-
lation at 28 to 37C but not at 42C [4]. In most clinical lab-
oratories, species identiﬁcation of the M. mucogenicum
complex relies upon the phenotypic characteristics deter-
mined by limited biochemical testing [35]. M. mucogenicum
isolates were found to be inconsistent, independent of the
carbon utilization tests for reliable identiﬁcation [36]. Species
identiﬁcation based on 16S rRNA, rpoB and hsp65 is the
most rapid and accurate method [2,37]. While the 16S
rRNA gene sequence of the M. aubagnense type strain dif-
fered from the M. mucogenicum type strain by 14 base pairs,
M. phocaicum shared 100% identity. Furthermore, rpoB and
hsp65 gene sequences contribute to unambiguously distin-
guishing among those organisms. M. aubagnense and M. phoc-
aicum shared, respectively, 95.5% and 90.1% rpoB sequence
identity with M. mucogenicum and 98.8% and 96% hsp65
sequence identity [2]. These methods allowed the differentia-
tion between M. mucogenicum species and ‘diphteroid spe-
cies’ [33].
Treatment of Infections due to the
M. mucogenicum Complex
Overall, M. mucogenicum complex isolates were the most
susceptible RGM species. They are susceptible to most anti-
microbial agents but, like other RGM, they are resistant to
ﬁrst-line antituberculous agents (isoniazid, rifampin, pyrazina-
mide…) [2,4,35]. Han et al. [14] reported that 100% (25/25)
of M. mucogenicum isolates were susceptible to amikacin,
cefoxitin, clarithromycin, imipenem and trimethoprim–sulfa-
methoxazole. In addition 88% (22/25) of isolates were sus-
ceptible to ciproﬂoxacin, and c. 50% were susceptible to
doxycycline and minocycline. M. aubagnense and M. phocai-
cum isolates were also found to be susceptible to those anti-
biotics (Table 2). M. mucogenicum complex isolates were also
susceptible to amoxicillin, amoxicillin-clavulanate, erythromy-
cin, azithromycin, oﬂoxacin, sparﬂoxacin, gatiﬂoxacin, levo-
ﬂoxacin, moxiﬂoxacin and linezolid [2,20,21,31] according to
the Clinical and Laboratory Standards Institute (CLSI) guide-
lines formerly NCCLS [38]. Despite the availability of these
in vitro data, the management of M. mucogenicum catheter-
related infection is largely based on clinical experience.
Timely intravascular catheter removal and initiation of appro-
priate antibiotic therapy are required to achieve successful
outcomes. An aminoglycoside combined with a macrolide
and/or a quinolone is the most common empirical regimen
[35]. The choice of antimicrobial therapy may ultimately be
guided by antimicrobial susceptibility testing. The optimal
duration of antimicrobial therapy for M. mucogenicum cathe-
ter-related infection is unknown. The duration of parenteral
therapy is usually 2–4 weeks, followed by oral therapy for
4–6 weeks.
TABLE 2. Antimicrobial suscept-
ibility of M. mucogenicum complex
species isolates
M. mucogenicum
(n = 25)
M. mucogenicum –like
(n = 1)
M. aubagnense
(n = 2)
M. phocaicum
(n = 4)
Amikacin 100% S 100% S 100% S 100% S
Cefoxitin 100% S 100% I 100% S 100% S
Ciproﬂoxacin 88%S, 12% I 100% S 100% S 100% S
Clarithromycin 100% S 100% S 100% S 100% S
Imipenem 100% S 100% S 100% S 100% S
TMP-SMZ 100% S 100% S 100% S 100% I
Doxycycline 67% S, 11%
I, 22% R
NT 100% S 100% S
Minocycline 45% S, 10%
I, 45% R
100% S 100% S 100% S
Reference [14] [14] [2] [2]
S, susceptible; I, intermediately susceptible; R, Resistant; TMP-SMZ, trimethoprim-sulfamethoxazole; NT, not tested.
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Prevention of Infections due to the
M. mucogenicum Complex
Catheter-related infections are the most clinically signiﬁcant
cases of M. mucogenicum infection [17]. The CDC guidelines
recommend covering intravenous catheters during bathing to
prevent opportunistic infections [38]. Bathing or showering
can wet CVCs at the distal IV catheter cap connections and
at the catheter entry to the chest. It is especially important
to educate all direct care providers, patients and family
members concerning the risks of water contamination of
CVCs during bathing and the methods to use during bathing
to minimize water contact indwelling.
The efﬁcacy of this policy has been shown since no fur-
ther cases of M. mucogenicum catheter–related infection
were observed after an outbreak [6,7]. Water samples
should be collected periodically and sent to the reference
laboratory for microorganism control. Also, logbooks should
be maintained for measurement of free chlorine concentra-
tion because low levels of chlorine in the water supply may
be associated with high levels of growth of M. mucogenicum
in tap water, posing a great risk to immunosuppressed
patients who have been exposed to this water while bathing
with unprotected CVCs and IV catheters.
Ecological Niche
Mycobacterium mucogenicum complex species are present in
both public and hospital water systems. In a study of 113
mycobacterial isolates from tap water from various geographi-
cal sites, the most frequently occurring (41%) nontuberculous
mycobacterium was M. mucogenicum [22]. This study under-
scored the potential threat of these ubiquitous organisms.
M. mucogenicum complex species have been found in various
aquatic environments around the world, including cooling
towers, pools and drinking water [22,25,27]. M. mucogenicum
complex species can form bioﬁlms and replicate within proto-
zoan hosts such as A. polyphaga which allow them to tolerate
disinfectants, chlorination and extreme temperatures [6–11].
This organism was found in shower water and in the air of a
stem cell transplant unit in relative high numbers during the
summer but not during the winter [40]. M. mucogenicum were
detected in a dental unit waterline before and after treatment
with an intermittent use, iodine-containing waterline cleaner
[41]. Recently, a closely related species of M. mucogenicum
was isolated from 6/45 units of peripheral blood stem cell
products (PBSC). The source of the contamination was traced
to ice cubes used in processing the PBSC products. However,
no adverse clinical consequences were observed with the
patients to whom the contaminated PBSC products were
given. Substituting reusable ice trays for an ice machine
resolved the outbreak [15]. Recently, chili sauces sold by
street venders in Mexico have been identiﬁed as a potential
source of M. mucogenicum infection [13].
Conclusions
Opportunistic M. mucogenicum complex species in water may
contaminate chemical devices and equipment and provide a
mechanism for bacterial invasion into the bloodstream.
Several immunosuppressed patients are at risk of signiﬁcant
morbidity and mortality from exposure to these health-care
environmental pathogens. Although, according to common
view, the extensive descriptive detail required for taxonomic
investigations of M. mucogenicum complex organisms is not
necessary for routine diagnostic laboratories, it is important
to identify the individual species because they can cause dif-
ferent diseases, they can have different susceptibility patterns
for certain drugs, and they have obvious epidemiological
links. Consideration should be given to M. mucogenicum com-
plex isolates as a possible cause of infection in the case of
positive blood cultures from immunocompromised patients.
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